Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations

Neoantigens derived from tumor-specific genetic mutations might be suitable targets for cancer immunotherapy because of their high immunogenicity. In the current study, we evaluated the immunogenicity of 10 driver mutations that are frequently expressed in various cancers using peripheral blood mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Iiizumi, Susumu, Ohtake, Junya, Murakami, Naoko, Kouro, Taku, Kawahara, Mamoru, Isoda, Fumiko, Hamana, Hiroshi, Kishi, Hiroyuki, Nakamura, Norihiro, Sasada, Tetsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406322/
https://www.ncbi.nlm.nih.gov/pubmed/30813491
http://dx.doi.org/10.3390/cancers11020266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406322/
https://www.ncbi.nlm.nih.gov/pubmed/30813491
http://dx.doi.org/10.3390/cancers11020266

Ejemplares similares